TY - JOUR
T1 - New field-in-field with two reference points method for whole breast radiotherapy
T2 - Dosimetric analysis and radiation-induced skin toxicities assessment
AU - Tekiki, Nouha
AU - Kuroda, Masahiro
AU - Ishizaka, Hinata
AU - Khasawneh, Abdullah
AU - Barham, Majd
AU - Hamada, Kentaro
AU - Konishi, Kohei
AU - Sugimoto, Kohei
AU - Katsui, Kuniaki
AU - Sugiyama, Soichi
AU - Watanabe, Kenta
AU - Yoshio, Kotaro
AU - Katayama, Norihisa
AU - Ogata, Takeshi
AU - Ihara, Hiroki
AU - Kanazawa, Susumu
AU - Asaumi, Junichi
N1 - Publisher Copyright:
© 2021, Spandidos Publications. All rights reserved.
PY - 2021
Y1 - 2021
N2 - The usefulness of the field-in-field with two reference points (FIF w/ 2RP) method, in which the dose reference points are set simultaneously at two positions in the irradiation field and the high-dose range is completely eliminated, was examined in the present study with the aim of decreasing acute skin toxicity in adjuvant breast radiotherapy (RT). A total of 573 patients with breast cancer who underwent postoperative whole breast RT were classified into 178 cases with wedge (W) method, 142 cases with field-in-field without 2 reference points (FIF w/o 2RP) method and 253 cases with FIF w/ 2RP method. Using the FIF w/ 2RP method, the high-dose range was the lowest among the three irradiation methods. The planning target volume (PTV) V105% and the breast PTV for evaluation (BPe) V105% decreased to 0.09 and 0.10%, respectively. The FIF w/ 2RP method vs. the FIF w/o 2RP method had a strong association (η) with PTV V105% (η=0.79; P<0.001) and BPe V105% (η=0.76; P<0.001). The FIF w/ 2RP method had a significant impact on lowering the skin toxicity grade in weeks 3 and 4, and increasing the occurrence of skin toxicity grade 0. The FIF w/ 2RP method vs. the W method had a moderate association with skin toxicity grade at week 3 (η=0.49; P<0.001). Using the FIF w/ 2RP method, the high-dose range V105% of the target decreased to 0%, and skin adverse events were decreased in conjunction. For patients with early-stage breast cancer, particularly patients with relatively small-sized breasts, the FIF w/ 2RP method may be an optimal irradiation method. Introduction.
AB - The usefulness of the field-in-field with two reference points (FIF w/ 2RP) method, in which the dose reference points are set simultaneously at two positions in the irradiation field and the high-dose range is completely eliminated, was examined in the present study with the aim of decreasing acute skin toxicity in adjuvant breast radiotherapy (RT). A total of 573 patients with breast cancer who underwent postoperative whole breast RT were classified into 178 cases with wedge (W) method, 142 cases with field-in-field without 2 reference points (FIF w/o 2RP) method and 253 cases with FIF w/ 2RP method. Using the FIF w/ 2RP method, the high-dose range was the lowest among the three irradiation methods. The planning target volume (PTV) V105% and the breast PTV for evaluation (BPe) V105% decreased to 0.09 and 0.10%, respectively. The FIF w/ 2RP method vs. the FIF w/o 2RP method had a strong association (η) with PTV V105% (η=0.79; P<0.001) and BPe V105% (η=0.76; P<0.001). The FIF w/ 2RP method had a significant impact on lowering the skin toxicity grade in weeks 3 and 4, and increasing the occurrence of skin toxicity grade 0. The FIF w/ 2RP method vs. the W method had a moderate association with skin toxicity grade at week 3 (η=0.49; P<0.001). Using the FIF w/ 2RP method, the high-dose range V105% of the target decreased to 0%, and skin adverse events were decreased in conjunction. For patients with early-stage breast cancer, particularly patients with relatively small-sized breasts, the FIF w/ 2RP method may be an optimal irradiation method. Introduction.
KW - Acute skin toxicity
KW - Breast cancer
KW - Dose distribution
KW - Dose reference point
KW - Field-in-field radiotherapy
KW - High-dose area eRub
UR - http://www.scopus.com/inward/record.url?scp=85112574131&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85112574131&partnerID=8YFLogxK
U2 - 10.3892/MCO.2021.2355
DO - 10.3892/MCO.2021.2355
M3 - Article
AN - SCOPUS:85112574131
SN - 2049-9450
VL - 15
JO - Molecular and Clinical Oncology
JF - Molecular and Clinical Oncology
IS - 3
M1 - 193
ER -